A new research perspective was published in Volume 13 of Oncoscience on March 11, 2026, titled 'Early success of the COCOON trial: Preventing dermatologic adverse events in first-line EGFR-mutant NSCLC.'
Impact Journals LLCApr 3 2026 A new research perspective was published in Volume 13 of Oncoscience on March 11, 2026, titled "Early success of the COCOON trial: Preventing dermatologic adverse events in first-line EGFR-mutant NSCLC.
" Led by first and corresponding author Bishal Tiwari from the Nassau University Medical Center and Asmita Koirala from the Western Regional Hospital in Nepal, the commentary summarizes interim findings from the phase II COCOON trial, which tested whether a structured dermatologic prophylaxis regimen could reduce skin toxicities in patients receiving first-line amivantamab plus lazertinib. The commentary describes a prophylactic protocol that included oral doxycycline or minocycline, ceramide-based moisturization, chlorhexidine nail care, and topical clindamycin. In the interim analysis, the COCOON regimen reduced moderate-to-severe dermatologic adverse events, with the incidence of grade ≥2 events falling from 76.5% with standard reactive care to 38.6% with prophylaxis. The paper also reports reductions in grade ≥3 events and treatment discontinuations, underscoring the practical value of proactive supportive care for EGFR-mutant non-small cell lung cancer. "The COCOON results emphasize the clinical value of anticipating EGFR inhibitor-related toxicities through multidisciplinary supportive care." The authors conclude that these results reinforce the need to integrate dermatologic prevention into first-line treatment planning for EGFR-mutant NSCLC. They note that straightforward, low-cost interventions can improve tolerability and maintain dose intensity, while future clinical practice updates will likely incorporate this kind of proactive supportive care approach more broadly. Journal reference:Tiwari, B., & Koirala, A. . Early success of the COCOON trial: Preventing dermatologic adverse events in first-line EGFR-mutant NSCLC. Oncoscience. DOI: 10.18632/oncoscience.648. https://www.oncoscience.us/article/648/text/
Cancer Cell Inflammation Lung Cancer Non-Small Cell Lung Cancer Paronychia Prophylaxis Rash Research Small Cell Lung Cancer
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Jim Goodwin surprised by Dundee United star's international snub but refuses to get involved in war of wordsCentre back Iurie Iovu wasn't selected for Moldova during the March international break
Read more »
Venezuela Oil Exports Top 1 Million Bpd in MarchVenezuela's crude exports jumped to about 1.09 million barrels per day last month, the highest rate in six months, as production rose and India became a key destination for shipments.
Read more »
Glasgow west end spot Five March launches weekly burger night with Korean menuRunning every Thursday, from 5pm until 9pm, the burger night will begin at the Elderslie Street food spot from April 9.
Read more »
Newcastle United star wins Premier League goal of the month for March 2026The Mag
Read more »
People's Postcode Lottery results: The winning streets from March 28 to April 3All the winning postcodes from this week's draw
Read more »
India's Russian Crude Imports Jump 90% in March After U.S. WaiverIndia's Russian crude imports jumped 90% in March after a U.S. sanctions waiver, as the de facto closed Strait of Hormuz disrupted Middle East supply.
Read more »